Blood Cancer Talks Trailer Bonus Episode 46 Season 1

Episode 45. Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi

Episode 45. Updates in Primary Myelofibrosis with Dr. Ayalew TefferiEpisode 45. Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi

00:00

00:00 01:00:53

Download

More episodes

Episode 45. Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi
61 min

Copied to clipboard

Apple Podcasts Spotify Pocket Casts Overcast Castro YouTube Goodpods Amazon Music Pandora CastBox Anghami Fountain JioSaavn Gaana iHeartRadio TuneIn Player FM SoundCloud Deezer Podcast Addict

Share Copied to clipboard

Embed Copied to clipboard

Blood Cancer Talks Trailer Bonus Episode 46 Season 1

Episode 45. Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi

May 29, 2024 Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff Full Transcript View the website

In this episode, we discuss updates in primary myelofibrosis with Dr. Ayalew Tefferi from the Mayo Clinic.
The key studies and trials discussed are as follows:

· GIPSS: Genetically inspired prognostic scoring system that is exclusively based on genetic markers.

§ https://www.nature.com/articles/s41375-018-0107-z

· MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis

§ https://ascopubs.org/doi/10.1200/JCO.2018.78.9867?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

· TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

§ https://ashpublications.org/blood/article/142/Supplement%201/620/502738/Transform-1-A-Randomized-Double-Blind-Placebo

· MANIFEST-2: Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

§ https://ashpublications.org/blood/article/142/Supplement%201/628/502728/Pelabresib-in-Combination-with-Ruxolitinib-for

· XPORT-MF-034: Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

Episode 45. Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi

Episode 45. Updates in Primary Myelofibrosis with Dr. Ayalew TefferiEpisode 45. Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi

More episodes

Episode 45. Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi

Subscribe

Share

Episode 45. Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi

Chapters